SYN - Synthetic Biologics, Inc.
| Previous Close | 0.6700 |
| Open | 0.6700 |
| Bid | 0.000 x 1100 |
| Ask | 0.000 x 1400 |
| Day's Range | 0.6700 - 0.7000 |
| 52 Week Range | 0.6500 - 21.0000 |
| Volume | 142,989 |
| Avg. Volume | 1,142,390 |
| Market Cap | 9.336M |
| Beta (3Y Monthly) | 2.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.102 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 90.50 |
- Thomson Reuters StreetEvents•15 hours ago
Edited Transcript of SYN earnings conference call or presentation 8-Nov-18 9:30pm GMT
Q3 2018 Synthetic Biologics Inc Earnings Call
- GlobeNewswire•8 days ago
Orchestra BioMed™ Appoints C. Evan Ballantyne as Chief Financial Officer
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief Financial Officer (CFO). Mr. Ballantyne is an experienced financial and strategic leader in the biotech, medical device and information services industries with a proven track record of building and strengthening a company’s financial position during his career of more than 25 years. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, commented, “Over the course of his career, Evan has played key roles in successfully leading companies in the full range of strategic options in financing including private equity and public offerings.
- GlobeNewswire•15 days ago
Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•20 days ago
New Trends in Healthcare Push Stocks Higher: 5 Picks
New healthcare trends backed by split party control of Congress are likely to boost industry stocks.
- ACCESSWIRE•21 days ago
New Healthcare Trends Could Push Sector Stocks Higher
CORAL GABLES, FL / ACCESSWIRE / November 21, 2018 / Healthcare stocks continue to gain traction amid volatile market conditions this week. Investors have been less optimistic on tech stocks and more favorable to the healthcare sector. US midterm elections have also helped to boost a more favorable market for healthcare.
- PR Newswire•21 days ago
Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development
ROCKVILLE, Md., Nov. 21, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss development of SYN-004 (ribaxamase) for the prevention of antibiotic-mediated Clostridium difficile infection (CDI). Pursuant to the meeting, the FDA has proposed criteria for Phase 3 clinical efficacy and safety which, if achieved, may support submission for marketing approval of ribaxamase on the basis of a single Phase 3 clinical trial.
- Associated Press•last month
Synthetic Biologics: 3Q Earnings Snapshot
The Rockville, Maryland-based company said it had a loss of 93 cents per share. In the final minutes of trading on Thursday, the company's shares hit 88 cents. A year ago, they were trading at $24.30. ...
- PR Newswire•last month
Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results
-- Announced Agreement with Cedars-Sinai Medical Center to Co-fund a Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Strengthened Balance Sheet in Support of ...
- PR Newswire•last month
Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018
-- Conference Call Scheduled for Thursday, November 8, 2018 at 4:30 p.m. EDT -- ROCKVILLE, Md. , Oct. 30, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
- Simply Wall St.•2 months ago
Does Synthetic Biologics Inc (NYSEMKT:SYN) Have A High Beta?
If you own shares in Synthetic Biologics Inc (NYSEMKT:SYN) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- PR Newswire•2 months ago
Synthetic Biologics Announces Closing of $18,639,000 Public Offering
The securities offered by the Company consist of (i) Class A Units consisting of 2,520,000 shares of Common Stock and Warrants to purchase 2,520,000 shares of Common Stock at a combined price of $1.15 per Class A Unit, and (ii) Class B Units consisting of 15,723 shares of Series B Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into an aggregate of 13,672,173 shares of Common Stock, and Warrants to purchase 13,672,173 shares of Common Stock. The Warrants will have an exercise price of $1.38, will be exercisable upon issuance and will expire five years from the date of issuance.
- GlobeNewswire•2 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Hyatt Hotels, E.W. Scripps, Cardtronics, Lincoln National, Synthetic Biologics, and Herc — New Research Emphasizes Economic Growth
NEW YORK, Oct. 12, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- PR Newswire•2 months ago
Synthetic Biologics Prices $18,000,000 Public Offering
The securities offered by the Company consist of (i) Class A Units consisting of 2,520,000 shares of Common Stock and Warrants to purchase 2,520,000 shares of Common Stock at a combined price of $1.15, and (ii) Class B Units consisting of 15,102 shares of Series B Convertible Preferred Stock, with a stated value of $1,000 per share, and convertible into an aggregate of 13,132,173 shares of Common Stock, and Warrants to purchase 13,132,173 shares of Common Stock. The Warrants will have an exercise price of $1.38, will be exercisable upon issuance and will expire five years from the date of issuance.
- Simply Wall St.•2 months ago
Who Are The Major Shareholders Of Synthetic Biologics Inc (NYSEMKT:SYN)?
The big shareholder groups in Synthetic Biologics Inc (NYSEMKT:SYN) have power over the company. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have Read More...
- PR Newswire•3 months ago
Synthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C
ROCKVILLE, Md., Sept. 6, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced it has entered into an agreement with Cedars-Sinai Medical Center for an investigator-sponsored Phase 2 clinical study of SYN-010. The study will provide further evaluation of the efficacy and safety of SYN-010, the Company's modified-release reformulation of lovastatin lactone, which is exclusively licensed to the Company by Cedars-Sinai Medical Center. SYN-010 is designed to reduce methane production by certain microorganisms (M. smithii) in the gut to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).
- PR Newswire•3 months ago
Synthetic Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
ROCKVILLE, Md. , Aug. 30, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore ...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of SYN earnings conference call or presentation 8-Aug-18 8:30pm GMT
Q2 2018 Synthetic Biologics Inc Earnings Call
- Benzinga•4 months ago
What Goes Through The Mind of A Trader When Taking A Position?
I’ve spoken at length about the technical and charting factors that I take account of when looking for trading setups. Obviously momentum is the main factor that I prioritize, along with the stock’s recent ...
- Associated Press•4 months ago
Synthetic Biologics: 2Q Earnings Snapshot
On a per-share basis, the Rockville, Maryland-based company said it had a loss of 3 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- PR Newswire•4 months ago
Synthetic Biologics Reports Second Quarter 2018 Operational Highlights and Financial Results
-- SYN-004 End of Phase 2 Meeting with U.S. Food & Drug Administration on Track for Third Quarter of 2018 -- -- Conference Call Today, August 8, 2018, at 4:30 p.m. (EDT) -- ROCKVILLE, Md. , Aug. 8, 2018 ...
- ACCESSWIRE•4 months ago
Synthetic Biologics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Synthetic Biologics, Inc. (NYSE American: SYN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 ...
- Simply Wall St.•4 months ago
Is Now The Time To Bet On The Healthcare Sector And Synthetic Biologics Inc (NYSEMKT:SYN)?
Synthetic Biologics Inc (NYSEMKT:SYN), a US$15.98m small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...
- PR Newswire•4 months ago
Synthetic Biologics Announces Reverse Stock Split
ROCKVILLE, Md., Aug. 1, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, announced today a reverse stock split of its issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every thirty-five (35) shares of common stock, effective August 10, 2018 (the "Effective Date"). The Company's common stock will begin trading on a split-adjusted basis when the market opens on August 13, 2018. The reverse stock split was authorized by the Company's Board of Directors on July 31, 2018.
- PR Newswire•4 months ago
Synthetic Biologics to Report Second Quarter 2018 Operational Highlights and Financial Results on August 8, 2018
-- Conference Call Scheduled for Wednesday, August 8, 2018 at 4:30 p.m. EDT -- ROCKVILLE, Md. , July 31, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company ...
